{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:14Z","timestamp":1792553414212,"version":"4.5.0"},"reference-count":77,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100013342","name":"nihr imperial biomedical research centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"imperial college london","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in psychedelic trials are usually required to discontinue SNRI\/SNRIs prior to enrolling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Using data from a recent clinical trial examining the comparative efficacy the psychedelic drug psilocybin (P) combined with approximately 20 h of psychological support to a 6-week (daily) course of the SSRI escitalopram plus matched psychological support for major depressive disorder, we explored the effects of discontinuing SSRI\/SNRIs prior to study enrolment on study outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Exploratory post hoc analyses using linear mixed effects model were performed to investigate the discontinuation effect on various validated depression symptom severity scales and well-being. The impact of SSRI\/SNRIs discontinuation on the acute psychedelic experience was also explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/outcomes:<\/jats:title>\n                    <jats:p>In the psilocybin group, there was a reduced treatment effect on all outcome measures for SSRI\/SNRIs discontinuers compared with unmedicated patients at trial entry. However, no effects of discontinuation on measures of the acute psychedelic experience were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Discontinuation of SSRI\/SNRIs before psilocybin might diminish response to treatment; however, as we did not test SSRI\/SNRI continuation in our trial, we cannot infer such causation. Moreover, the exploratory nature of the analyses makes them hypothesis generating, and not confirmatory. A controlled trial of SSRI\/SNRI discontinuation versus continuation prior to psilocybin is urgently required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811241237870","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T01:43:03Z","timestamp":1711158183000},"page":"458-470","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-6211","authenticated-orcid":false,"given":"David","family":"Erritzoe","sequence":"first","affiliation":[{"name":"Division of Psychiatry, Department Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-4628","authenticated-orcid":false,"given":"Tommaso","family":"Barba","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J","family":"Spriggs","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando E","family":"Rosas","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, UK"},{"name":"Department of Informatics, University of Sussex, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Nutt","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-7150","authenticated-orcid":false,"given":"Robin","family":"Carhart-Harris","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, UK"},{"name":"Departments of Neurology and Psychiatry, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2022.565"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116678781"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115609019"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i01"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08672"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa6703_13"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2487"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyac075"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.170022"},{"key":"e_1_3_4_12_1","first-page":"255","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria","volume":"25","author":"Black K","year":"2000","unstructured":"Black K, Shea C, Dursun S, et al. (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria. J Psychiatry Neurosci 25: 255\u2013261.","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00145-4"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-90"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.5334\/joc.10"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3008-z"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109398"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.118.017160"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117725915"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006117.pub2"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115581093"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-9536.2011.00037.x"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.796"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068884"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370338"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05710-w"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.2017.3826","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich MJ","year":"2017","unstructured":"Friedrich MJ (2017) Depression is the leading cause of disability around the world. JAMA 317: 1517\u20131517.","journal-title":"JAMA"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0361-9230(01)00623-2"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17522439.2018.1469163"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211039327"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231179910"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116677852"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211032051"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30032-X"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81446-7"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138661"},{"key":"e_1_3_4_45_1","first-page":"63","article-title":"Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain","volume":"19","author":"Klimek V","year":"1994","unstructured":"Klimek V, Zak-Knapik J, Mackowiak M (1994) Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J Psychiatry Neurosci 19: 63\u201367.","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3007-12.2013"},{"key":"e_1_3_4_47_1","first-page":"289","article-title":"[Changes in 5-HT2 receptor density induced by repeated treatment with 5-HT uptake inhibitor or 5-HT agonist]","volume":"9","author":"Kubota M","year":"1989","unstructured":"Kubota M, Ueno K, Yamano M, et al. (1989) [Changes in 5-HT2 receptor density induced by repeated treatment with 5-HT uptake inhibitor or 5-HT agonist]. Yakubutsu Seishin Kodo 9: 289\u2013292.","journal-title":"Yakubutsu Seishin Kodo"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcz025"},{"key":"e_1_3_4_49_1","first-page":"746","article-title":"An introduction to multiplicity issues in clinical trials: The what, why, when and how","volume":"46","author":"Li G","year":"2017","unstructured":"Li G, Taljaard M, Van den Heuvel ER, et al. (2017). An introduction to multiplicity issues in clinical trials: The what, why, when and how. Int J Epidemiol 46: 746\u2013755.","journal-title":"Int J Epidemiol"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00035"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0324-9"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2020.02.001"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05876-x"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.1.78"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000137184.64610.c8"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2000.0619"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434"},{"key":"e_1_3_4_60_1","unstructured":"National Institute for Health and Care Excellence. (2022 June 29). Depression in adults: treatment and management (NICE Guideline No. NG222). https:\/\/www.nice.org.uk\/ng222"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00269"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.65"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211066709"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v03n0404"},{"key":"e_1_3_4_69_1","first-page":"241","article-title":"Human hallucinogen interactions with drugs affecting serotonergic neurotransmission","volume":"7","author":"Strassman RJ","year":"1992","unstructured":"Strassman RJ (1992) Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 7: 241\u2013243.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-63"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00141-3"},{"key":"e_1_3_4_72_1","first-page":"19","article-title":"Receptor alterations associated with serotonergic agents: An autoradiographic analysis","volume":"48","author":"Wamsley JK","year":"1987","unstructured":"Wamsley JK, Byerley WF, McCabe RT, et al. (1987) Receptor alterations associated with serotonergic agents: An autoradiographic analysis. J Clin Psychiatry 48: 19\u201325.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_73_1","first-page":"449","article-title":"Antidepressant discontinuation syndrome","volume":"74","author":"Warner CH","year":"2006","unstructured":"Warner CH, Bobo W, Warner C, et al. (2006) Antidepressant discontinuation syndrome. Am Fam Physician 74: 449\u2013456.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/5x2bu."},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231167848"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1037\/xge0000014"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00194"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200102000-00010"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241237870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811241237870","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241237870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:39Z","timestamp":1777507899000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811241237870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1177\/02698811241237870"],"URL":"https:\/\/doi.org\/10.1177\/02698811241237870","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}